Biological Responses Affecting Early-stage Dental Implant Placement in Patients With History of Periodontitis

Periodontitis Clinical Trial

Official title:

Identification of Biological Responses as a Causal Link for the Increased Peri-implantitis in Patients With History of Periodontitis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05834946
• Other study ID #: DF RD2002/0002
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 4, 2021
• Est. completion date: May 30, 2025

Study information

• Verified date: April 2023
• Source: University of Malaya
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective parallel, double-blind, four-arm randomised controlled clinical study is planned to assess the difference in the level of the inflammatory biomarkers expressed following the placement of the first dental implant in patients with history of periodontitis (successfully treated) and healthy controls without the disease, during implant osseointegration period. The subjects in both groups will also be randomised to receive one of the two types of implants provided which have different surface treatment.

Description:

This is a prospective, parallel, double-blind, four-arm randomised clinical control study, aims to investigate the changes of clinical parameters and pro-inflammatory biomarkers expression and the shift following the first dental implant placement in patients who have been successfully treated for periodontitis, compared with healthy control without the disease.

The main questions to answer are:

1. Why do patients with history of periodontitis are at a greater risk to develop peri-implantitis than patients without history of periodontitis?

2. Is there any difference in the microbial composition, histological and immunological reaction of the host's dental plaque, peri-implant soft tissue, gingival crevicular fluids (GCF) of adjacent teeth and peri-implant sulcular fluids (PISF) following implant placement in patients with and without a history of periodontitis? The test group will consist of subjects with stabilised periodontitis, whilst the control group will consist of healthy patients with no history of periodontitis, as identified via history taking and clinical screening. Periodontal condition will be determined based on the new 2017 periodontal classification. All participants in both groups will be randomised to receive one of two types of implants with different surface treatment.

Clinical measurement, GCF and PISF will be collected around the single implant and adjacent teeth, at the following stages (time-point):

• Baseline (pre-operative)

• After implant placement (prior to the second stage surgery)

• After implant exposure (prior to the crown restoration)

• 3-month after the implant is restored

• Soft tissue will be obtained during the first stage (baseline) and second stage implant surgery (post-operative) and analysed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 29
• Est. completion date: May 30, 2025
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Specific inclusion criteria for test group:

• History of periodontitis but currently stable

• Must have successfully completed active periodontal treatment at least 4 months prior to the commencement of study

2. Specific inclusion criteria for control group:

• No history of periodontitis, with minimal age-related radiographic bone loss

• Reason for losing the tooth/teeth was not due to periodontal problem

3. General inclusion criteria:

• Medically healthy

• Aged between 30 to 65 years old

• Non-smoker, or quit smoking at least 12 months before study commencement

• Good oral hygiene (full mouth plaque score (FMPS)<20%, full mouth bleeding score (FMBS)<15%)

• Indicated for a single implant placement in the posterior region, with adjacent and contralateral natural tooth

• Intact inter-cuspal position

Exclusion Criteria:

• Previous history of dental implant placement

• Currently pregnant or intend to be pregnant, and/or lactating mothers

• Taking long-term medicines which may affect gingival tissue and oral microbiome, e.g. antibiotics, anticoagulants, anticonvulsants, immunosuppressants and calcium channel blockers.

Related Conditions & MeSH terms

• Mucositis
• Peri-implant Mucositis
• Peri-Implantitis
• Periodontitis

Intervention

Other:
• Megagen implant placement
Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
• Biomate-Swiss implant
Biomate-Swiss implant with precision dimension laser (PDL) surface

Locations

Country	Name	City	State
Malaysia	Faculty of Dentistry, University of Malaya	Kuala Lumpur	Wilayah Persekutuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Malaya

Country where clinical trial is conducted

Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of matrix metalloproteinase (MMP)-8 expressed in the gingival crevicular and peri-implant sulcular fluids during the early-stage of dental implant placement	To measure the absolute quantification of MMP-8 level expressed during the implant osseointegration period in all study groups via ELISA method.	From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) and 3-months after implant crown restoration (final visit- TP4)
Secondary	Shift of the microbial composition in the supragingival dental plaque, identified via 16S rRNA next generation sequencing	Identification and comparison of supragingival dental plaque bacteria species/genus and the shift of the bacterial composition during the early-stage of dental implant placement between study groups	From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4)
Secondary	Shift of proteome profiles in the gingival crevicular and peri-implant sulcular fluids during the early-stage of dental implant placement	To assess the protein profile and levels of expression of the pro-inflammatory cytokines in GCF and gingival tissue via liquid chromatography-electrospray ionization tandem mass spectrometry (LC-MS) proteomic analysis following osseointegration.	From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4)
Secondary	Histological changes in the peri-implant soft tissue before and after implant placement	Number and co-localisation of cells with MMP-8, pro-inflammatory (M1)- and anti-inflammatory (M2)-related cytokines via hematoxylin and eosin staining, immunohistochemistry and immunofluorescence analysis	Between first stage (baseline/pre) and second stage implant surgery (post-operative) at 3 months after the first surgery
Secondary	Changes in the clinical parameters during the early-stage implant placement	To assess intra-oral clinical parameters changes (i.e. patient-level and tooth-level mean periodontal pocket depth (mm) and clinical attachment level (mm); full mouth plaque score (%) and bleeding score (%)) following the first dental implant placement, each time-point (TP). The deeper the depth/higher the level or percentage means the worse the condition is.	From baseline (1st time-point (TP1)) to 1st stage surgery (implant placement - TP2), after 2nd stage surgery (implant exposure (TP3) approximately 3 months after the 1st stage surgery) and 3-months after implant crown restoration (final visit- TP4)